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ABSTRACT
Purpose. This prospective observational study aimed to evaluate the impact of 
adjuvant chemotherapy on biological and clinical markers of aging and frailty.
Methods. Women ≥ 70 years old with early breast cancer were enrolled after 
surgery and assigned to a chemotherapy (Docetaxel and Cyclophosphamide) group 
(CTG, n=57) or control group (CG, n=52) depending on their planned adjuvant 
treatment. Full geriatric assessment (GA) and Quality of Life (QoL) were evaluated at 
inclusion (T0), after 3 months (T1) and at 1 year (T2). Blood samples were collected 
to measure leukocyte telomere length (LTL), levels of interleukin-6 (IL-6) and other 
circulating markers potentially informative for aging and frailty: Interleukin-10 (IL-
10), Tumor Necrosis Factor Alpha (TNF-α), Insulin-like Growth Factor 1 (IGF-1), 
Monocyte Chemotactic Protein 1 (MCP-1) and Regulated on Activation, Normal T cell 
Expressed and Secreted (RANTES).
Results. LTL decreased significantly but comparably in both groups, whereas IL-6 
was unchanged at T2. However, IL-10, TNF-α, IGF-1 and MCP-1 suggested a minor 
biological aging effect of chemotherapy. Clinical frailty and QoL decreased at T1 in 
the CTG, but recovered at T2, while remaining stable in the CG. 
Conclusion. Chemotherapy (TC) is unlikely to amplify clinical aging or induce 
frailty at 1 year. Accordingly, there is no impact on the most established aging 
biomarkers (LTL, IL-6). 
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INTRODUCTION
The incidence of breast cancer, the most frequent 
tumor occurring in women, increases with age. While 
adequate treatment can improve outcome and survival in 
the elderly, concerns over side effects or the idea of futility 
result in a lower use of adjuvant chemotherapy in this 
patient population. This might be one of the reasons why 
cancer-related mortality is higher in older patients [1]. The 
high variability of individual health status constitutes a 
major challenge in offering optimal therapy to the elderly. 
A comprehensive geriatric assessment (GA), evaluating 
functional status, comorbidity, socio-economic condition, 
nutrition and polypharmacy, is therefore necessary, and 
has been recommended by the International Society 
of Geriatric Oncology (SIOG) [2]. Based on our own 
findings, biological markers of aging and frailty could add 
on to this clinical evaluation [3, 4]. 
In line with the complexity of the aging process, 
a huge variety of potential aging biomarkers has been 
described. A crucial role has been attributed to telomeres, 
in cells and tissues subjected to replicative aging. They 
are incompletely replicated in somatic cells and shorten 
with each cellular division. Therefore, leukocyte 
telomere length (LTL) can serve as a marker of a cell’s 
replicative “age” [5], and, in extension, can mirror a 
person’s biological age [6]. LTL correlates with several 
aging-related syndromes [7]. An increasing low-grade 
chronic inflammatory status, reflected by an altered 
plasma level of multiple inflammatory mediators [8-10], 
is another hallmark of aging. Levels of interleukin-6 (IL-
6) and tumor necrosis factor alpha (TNF-α) continuously 
rise with age, and have been associated with several 
aging-related syndromes [11-13]. Conversely, the anti-
inflammatory cytokine interleukin-10 (IL-10) tends to 
decrease in blood during aging [14] and age-related 
diseases [15]. Furthermore, several chemokines also 
change during aging [16-19] : Monocyte Chemotactic 
protein 1 (MCP-1) blood levels are higher in older people 
compared to younger individuals [20-22]. Regulated 
on Activation, Normal T cell Expressed and Secreted 
(RANTES), has shown to undergo age-related changes as 
well, although, results from the literature are not consistent 
[21, 22]. Additionally, perturbation of the insulin/insulin-
like growth factor 1 (IGF-1) metabolic pathway has been 
implicated in aging-related disease, and reduced longevity 
in both animal models [23-25] and humans [26, 27, 12]. 
Chemotherapy may influence the aging process 
via a variety of different mechanisms. Firstly, anticancer 
agents can induce cellular senescence through DNA 
damage [28], either directly or indirectly via generation 
of free radical intermediates and inhibition of DNA repair 
enzymes. Secondly, chemotherapy may specifically 
accelerate telomere attrition in leukocytes, most likely 
due to direct telomere damage or possibly by inhibition 
of the enzyme telomerase [29]. Repeated cycles of 
intense hematological repopulation during chemotherapy 
may shorten telomeres more rapidly if telomerase is not 
compensating for endochromosomal DNA loss [30-32]. 
Such effects of anticancer drugs on the replicative capacity 
of blood cells may be more pronounced in older compared 
to younger patients [33]. Finally, neuroendocrine and 
immune functions can also be affected by chemotherapy 
and by corticosteroids that are often incorporated in 
chemotherapeutic regimens [34]. Chemotherapy might 
thus be expected to accelerate aging [35, 36, 33, 37, 38]. It 
has been hypothesized that an increased rate of molecular 
aging might explain some of the delayed adverse events 
linked to chemotherapy [39]. However, long-term follow-
up data, on both clinical and biological repercussions of 
chemotherapeutic treatments, have never been reported 
To ensure optimal treatment decisions in older 
patients, it is of utmost importance to further elucidate the 
impact of chemotherapy on the aging process, not only 
biologically, but most particularly in terms of clinical 
repercussion. Here, we report a prospective study to assess 
the effect of chemotherapy on biological and clinical aging 
markers in older patients with breast cancer.
RESULTS
In total, 109 consecutive subjects were enrolled 
in the study: 57 in the chemotherapy group (CTG) and 
52 in the control group (CG). Almost all CTG patients 
completed their adjuvant chemotherapy. One patient 
stopped after the first cycle, one after the second cycle and 
two patients after the third cycle because of adverse events 
(allergy, severe infection and overall intolerance). Two 
other patients stopped after 1 cycle because of an allergic 
reaction, but resumed chemotherapy with a taxane-free, 
anthracyclin containing regimen. Baseline tumor and 
treatment characteristics are described in Table 1.
Results of the different biomarker assays at the 
3 time points (T0, inclusion; T1, at 3 months; T2, at 1 
year) and their evolution over time are shown in Table 2 
and Figure 1. In brief, LTL was similar in both cohorts 
at inclusion, and decreased to the same extent in both 
groups, indicating no difference in evolution in the two 
cohorts (test for interaction p=0.88). Also for RANTES, 
the evolution was similar in both groups. In contrast, 
the other 5 biomarkers remained stable in the CG while 
significantly changing in the CTG. IL-6 decreased at T1 
and returned to initial levels at T2; MCP-1 decreased at T1 
but increased above baseline value at T2; IGF-1 showed a 
similar initial decline at T1 but only slightly recovered at 
T2. On the other hand, IL-10 increased at T1 but decreased 
at T2 and TNF-α levels were increased at both T1 and T2. 
To determine if differences in baseline frailty between 
groups could have influenced these results, we repeated 
the time interaction analysis correcting for frailty at T0. 
This analysis showed similar results (Table 2).
For background on geriatric assessment and our 
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newly developed frailty score the ‘Leuven Oncogeriatric 
Frailty Score (LOFS)’, we refer to the section patients and 
methods and appendix 1. GA results at the 3 time points, 
and the differential evolution over time (with and without 
correction for frailty) are displayed in Table 3 and Figure 
2. A significant interaction test, pointing to a differential 
evolution in time between both groups, was found for 
LOFS, instrumental activities of daily living (iADL), 
Mini Nutritrional Assessment – short form (MNA-SF) and 
Global Quality of Life (Global QoL), while this test was 
not significant for Activities of Daily Living (ADL), Mini 
Mental Status Evaluation (MMSE), Geriatric Depression 
Scale - 15 (GDS-15) and Charlson Comorbidity Index 
(CCI). A marked decline in LOFS, iADL, MNA-SF and 
Global QoL was noted at T1 in the CTG but not CG. 
However, all significant differences noted at T1 in the CTG 
returned to normal at T2. No significant modifications of 
frailty level according to Balducci were found in either 
of the two groups: the odds ratio for being fit rather than 
vulnerable, or vulnerable rather than frail according to this 
index was 0.90 (95% CI 0.27-3.07) from T0 to T1 and 
0.63 (95% CI 0.21-1.90) from T0 to T2 in the CTG, and 
there was no difference with the CG (test for interaction 
p=0.63) (see Figure 2A). 
Within the CTG we explored the influence of 
baseline frailty on the time evolution of biological and 
clinical aging markers. Because the very small number 
of truly frail patients in this chemotherapy group, we 
chose to dichotomise the patients comparing fit patients 
to vulnerable+frail patients according to Balducci, and 
patients with LOFS ≥ 8 to patients with LOFS < 8). 
Except for LTL evolution, that showed a significant 
time interaction with frailty status (p=0.04 for Balducci 
dichotomization and p=0.01 for LOFS dichotomization), 
no differences in evolution according to frailty status at 
the start were seen for other biomarkers. As for the clinical 
aging parameters, the evolution over time according to 
baseline frailty status showed to be different for MNA and 
Global Health (significant time interaction with Balducci 
category; p=0.02 and p=0.01 respectively) and for GDS 
and Falls (significant time interaction with LOFS category; 
p=0.04 and p=0.01 respectively), but not for CCI, ADL, 
iADL and MMSE.
Correlations of baseline (T0) aging biomarkers 
with chronological age and LOFS are shown in Table 
4. LTL showed a significant correlation with LOFS but 
not with chronological age. Of all biomarkers, IL-6 was 
most strongly associated with both chronological age 
and LOFS: the higher IL-6, the higher chronological 
age and the lower the LOFS. TNFα showed a strong and 
highly significant positive correlation with chronological 
age. Associations with other aging biomarkers were not 
significant.
Adverse events occurring during the study 
period were recorded at 3 months and at one year, and 
are summarized in Table 5. As expected, toxicity was 
Table 1: Baseline patient and tumor characteristics
Chemo Group
(n = 57)
Control Group 
(n = 52)
Age
Median, years (range) 73.5 (70-80) 75.0 (70-90)
pT 
1 
2 
3 
4 
n (%)
11 ( 19)
37 ( 65)
6 (11)
3 (5)
n (%)
21 (40)
30 (58)
0 (0)
1 (2)
pN 
0 
1-3 
n (%)
18 (33)
36 (67)
n (%)
27 (53)
24 (47)
Breast cancer phenotype§
Basal like 
HER2 positive (ER negative) 
Luminal A 
Luminal B HER2 negative 
Luminal B HER2 positive 
n (%)
11 (19)
6 (10)
9 (16)
22 (39)
9 (16)
n (%)
0 (0)
0 (0)
35 (67)
16 (31)
1 (2)
Adjuvant therapy 
   TC chemotherapy 
   G-CSF primary prophylaxis 
   Trastuzumab 1 year 
   Endocrine therapy 
   Radiotherapy 
n (%)
56 (100)
48 (86)
15 (27)
40 (71) 
46 (82)
n (%)
0 (0)
0 (0)
0 (0)
52 (100)
32 (62)
Abbreviations : ER : Estrogen Receptor; TC : Docetaxel-Cyclophosphamide; G-CSF : Granulocyte-Colony Stimulating Factor
§: Breast cancer phenotype : see ref 47 in manuscript, Goldhirsh et al.
Oncotarget4www.impactjournals.com/oncotarget
markedly more frequent in the CTG, particularly during 
treatment (i.e. between T0 and T1). We also assessed 
whether any of the aging biomarkers could predict the 
occurrence of grade II-III-IV toxicity at 3 months in the 
CTG. Analyses were performed for toxicity parameters 
that occurred in at least 5 patients. None of the aging 
biomarkers at baseline (T0) predicted development of 
grade II or higher toxicity, and neither did the Balducci 
score or LOFS (data not shown). 
Unplanned readmissions occurred between 0 and 
3 months in 12 patients (22%) of the CTG (N=54) and 
3 patients (6%) of the CG (N=50). Between 3 and 12 
months, these numbers were 9 (18%) for the CTG and 
15 (32%) for the CG. However, none of the biomarkers 
at baseline (T0) nor Balducci or LOFS predicted an 
unplanned readmission during chemotherapy.
DISCUSSION
Geriatric oncology is a growing discipline. Older 
breast cancer patients have a higher cancer-specific 
mortality [1], probably because therapy is withheld on 
concerns over side effects. Is this fear justified and are 
these suspected side effects actually related to the aging 
process? Some studies seem to show an accelerating 
effect of chemotherapy on the aging process [33, 35, 
36, 38]. One could anticipate an increase in geriatric 
problems after chemotherapy. This could mislead the 
oncologist not to administer chemotherapy where it 
would otherwise have been indicated. However, data on 
this topic still remain disparate to date. DNA damage (and 
DNA damaging drugs) are suggested not necessarily to 
cause or accelerate aging [40], and no report exists that 
investigated alterations in aging biomarkers, attributed 
to chemotherapy, show an impact on clinical outcome. 
Therefore, we prospectively compared clinical and as well 
as potential biological aging markers in a cohort of older 
breast cancer patients given or not given chemotherapy 
after surgery. The patients were all >70 years of age, thus 
investigating a truly ‘older’ population. In those patients, 
geriatric assessment often reveals previously unknown 
age-related problems [2]. 
After 1 year of follow-up, we found that 
chemotherapy did not significantly influence established 
markers of clinical frailty. Our data only revealed a 
mild and transient decrease of global fitness status in 
older breast cancer patients undergoing chemotherapy: 
increased clinical frailty, as evidenced by a lower LOFS 
score, was noted in the CTG (but not CG) after 3 months 
of treatment, but the frailty status returned to baseline 
level after one year. Frailty status according to Balducci 
did not change during the time course of the study. Global 
QoL was also slightly decreased at 3 months in the CTG 
(but not the CG), but was also restored after 1 year. The 
temporary decrease in fitness and QoL is not unexpected, 
and can be explained by acute and subacute chemotherapy 
toxicity. However, our study has proven that overall, the 
TC regimen [41-43] (generally administered with primary 
G-CSF support) is well tolerated in older breast cancer 
patients. Apart from febrile neutropenia (13% grade III), 
we noticed few grade III, and even no grade IV side 
effects.
Abbreviations. SD: Standard Deviation; CI: Confidence Interval; LTL: Leukocyte Telomere Length; IL-6: Interleukin-6; IL-
10: Interleukin-10; TNF-alpha: Tumor Necrosis Factor Alpha; MCP-1: Monocyte Chemotactic Protein 1; RANTES: Regulated 
Upon Activation, Normal T cell Expressed and presumably Secreted; IGF-1: Insulin Like Growth Factor 1
p-values in italic font show results corrected for patient frailty level at baseline
Table 2: Aging biomarker results at baseline (T0), 3 months (T1), and 1 year (T2), and their differential evolution over 
time in Chemo and Control Groups
Chemo Group
(n=57)
Evolution Over 
Time
Chemo Group
Control Group
(n=52)
Evolution Over 
Time
Control Group
Differential 
Evolution Chemo 
and Control 
(TimeInteraction)
T0 T1 T2 T0T1 T0T2 T0 T1 T2 T0T1 T0T2
LTL N
   T/S mean +/- SD
45
0.7 +/- 0.2
46
0.7 +/- 0.3
49
0.6 +/- 0.2
p=0.05
p=0.05
p<0.01
p<0.01
41
0.7 +/-0.3
45
0.6 +/-0.15
44
0.6 +/-0.14
p=0.02
p=0.02
p<0.01
p<0.01
p=0.88
p=0.87
IL-6 N
   pg/mL mean +/- SD
56
3.2 +/- 3.7
55
2.3 +/- 3.7
51
4.5 +/- 9.2
p=0.02
p=0.02
p=0.27
p=0.26
52
7.0 +/-13.9
48
11.4 +/-38.5
46
5.6 +/-6.1
p=0.95
p=0.77
p=0.66
p=0.45
p<0.01
p<0.04
IL-10 N
   pg/mL mean +/- SD
51
0.3+/- 0.4
50
0.3 +/- 0.3
47
0.2 +/- 0.1
p=0.05
p=0.01
p<0.01
p<0.01
50
0.2 +/-0.2
47
0.2 +/-0.2
46
0.2 +/-0.1
p=0.92
p=0.96
p=0.28
p=0.23
p<0.01
p<0.01
TNF-alpha N
   pg/mL mean +/- SD
56
2.5 +/- 10.1
55
2.9 +/- 9.7
51
3.3 +/- 9.6
p<0.01
p<0.01
p<0.01
p<0.01
52
2.3 +/-3.1
48
2.5 +/-3.4
46
2.5 +/-3.1
p=0.71
p=0.71
p=0.08
p=0.06
p<0.01
p=0.01
MCP-1 N
   pg/mL mean +/- SD
55
143 +/- 70
55
110.7 +/- 70
51
183.2+/- 48
p<0.01
p<0.01
p<0.01
p<0.01
52
189 +/-78
48
219 +/-131
46
207 +/-108
p=0.14
p=0.16
p=0.34
p=0.29
p<0.01
p<0.01
Rantes N
   pg/mL mean +/- SD
55
59562+/- 46691
55
61411+/- 53735
51
51903+/- 47600
p=0.78
p=0.83
p=0.01
p=0.01
52
59004 +/-43436
48
53215 +/-46461
46
55421 +/-48231
p=0.03
p=0.03
p=0.03
p=0.03
p=0.29
p=0.28
IGF-1 N
   ng/mL mean +/- SD
55
79 +/- 26
54
67 +/- 26
51
70 +/- 24
p<0.01
p<0.01
p<0.01
p<0.01
51
76 +/-36
48
77 +/-27
46
74 +/-34
p=0.31
p=0.35
p=0.48
p=0.64
p<0.01
p<0.01
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Figure 1: Evolution over time of aging biomarker results in the Chemo and Control Groups. * Designates statistical 
significant (p≤ 0.05) differences at T1 or T2, compared to T0, within the Chemo group (green asterisk) or the Control group (blue asterisk) 
A. Mean Leukocyte Telomere Length (+95% CI) by Time and Study Arm B. Mean IL-6 (+95% CI) by Time and Study Arm (based on log 
transformed data, UNIT pg/mL) C. Mean IL-10 (+95% CI) by Time and Study Arm (based on square root transformed data, UNIT pg/mL) 
D. Mean TNF-α (+95% CI) by Time and Study Arm (based on log transformed data, UNIT pg/mL) E. Mean IGF-1 (+95% CI) by Time and 
Study Arm (based on log transformed data, UNIT ng/mL) F. Mean MCP-1 by Time and Study Arm (based on log transformed data, UNIT 
pg/mL) G. Mean RANTES by Time and Study Arm (based on log transformed data, UNIT pg/mL).
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Table 4: Correlation of baseline aging biomarkers with chronological age and clinical aging (according to LOFS).
Chronological age (years) Clinical aging (LOFS)
Spearman
correlation p-value N
Spearman
correlation p-value N
Telomere length -0.11 0.32 86 -0.27 0.01 85
IL-6 0.32 <0.01 108 -0.21 0.03 106
IL-10 -0.03 0.78 101 -0.05 0.62 99
IGF-1 -0.01 0.33 106 -0.03 0.75 104
TNF-α 0.34 <0.01 108 -0.18 0.06 106
MCP-1/CCL-2 0.18 0.07 107 -0.14 0.16 105
RANTES/CCL-5 -0.01 0.88 107 0.16 0.10 105
Abbreviations. LOFS : Leuven Oncogeriatric Frailty Score; IL-6 : Interleukin-6; IL-10 : Interleukin-10; IGF-1 : Insulin Like 
Growth Factor-1; TNF-α : Tumor Necrosis Factor-α; MCP-1/CCL2 : Monocyte chemotactic protein-1/Chemokine (C-C motif) 
ligand 2; RANTES/CCL5 : Regulated Upon Activation, Normal T cell Expressed and presumably Secreted/ Chemokine (C-C 
motif) Ligand 5
Table 3: Geriatric assessment results at baseline (T0), 3 months (T1), and 1 year (T2), and their differential evolution 
over time in Chemo and Control Groups
Chemo Group
  
(n=57)
Evolution Over 
Time
Chemo Group
Control Group
(n=52)
Evolution Over Time 
Control Group
Differential Evolution
(Time Interaction)
T0 T1 T2 T0T1 T0T2 T0 T1 T2 T0T1 T0T2
Frailty(Balducci) N
Fit n (%)
Vulnerable n (%)
Frail n (%)
56
12 (21)
21 (35)
23 (41)
53
8 (15)
23 (43)
22 (42)
48
10 (21)
15 (31)
23 (48)
p=0.87 p=0.41
52
10 (19)
17 (33)
25 (48)
48
9 (19)
13 (27)
26 (54)
46
7 (15)
13 (28)
26 (57)
p=0.34 p=0.77 p=0.63α
LOFS N
Mean +/- SD
56
7.5 +/- 2
53
6.7 +/- 2
48
7.4 +/- 2 p<0.01 p=0.60
51
6.8 +/- 2
48
7.0 +/- 2
46
6.8 +/- 2 p=0.48 p=0.45 p<0.01
ADL N
Mean +/- SD
6§ n (%)
0-5 n (%)
56
5.5 +/- 1
33 (59)
23 (41)
56
5.4 +/- 1
35 (62)
21 (37)
51
5.5 +/- 1
30 (59)
21 (41)
p=0.88
p=0.88
p=0.96
p=0.99
52
5.1 +/- 1
29 (56)
23 (44)
48
5.0 +/- 1
23 (48)
25 (52)
46
5.0 +/- 1
21 (46)
25 (54)
p=0.94
p=0.85
p=0.57
p=0.47
p=0.77
p=0.76
IADL N
Mean +/- SD
8§ n (%)
0-7 n (%)
57
6.6 +/- 2
24 (42)
33 (58)
56
6.0 +/- 2
16 (29)
40 (71)
51
6.8 +/- 2
26 (51)
25 (49)
p<0.01
p=0.01
p=0.39
p=0.39
52
5.8 +/- 2
17 (33)
35 (67)
48
5.8 +/- 2
17 (35)
31 (65)
46
5.7 +/- 3
17 (37)
29 (63)
p=0.71
p=0.75
p=0.57
p=0.60
p<0.01
p=0.01
Previous falls N
   No n (%)
   Yes n (%)
57
44 (77)
13 (23)
N/A
50
34 (68)
16 (32)
N/A p=0.28p=0.25
52
28 (54)
24 (46)
N/A
46
29 (63)
17 (37)
N/A p=0.33p=0.37
p=0.15β
p=0.15 β
MMSE N
   Mean +/- SD
57
27.9 +/- 2
56
27.6 
+/- 3
51
27.9 +/- 3
p=0.22
p=0.19
p=0.94
p=0.96
52
27.9 +/- 2
48
27.8 +/- 3
46
27.9 +/- 4
p=0.34
p=0.31
p=0.40
p=0.41
p=0.77
p=0.78
GDS-15 N
   Mean +/- SD
   0-4§ n (%)
   5-15 n (%)
55
2.9 +/- 2
46 (84)
  9 (16)
56
3.1 +/- 2
43 (77)
13 (23)
50
3.1 +/- 3
38 (76)
12 (24)
p=0.31
p=0.23
p=0.50
p=0.51
46
2.8 +/- 2
35 (76)
11 (24)
47
3.5 +/- 3
32 (68)
15 (32)
45
3.1 +/- 3
35 (78)
10 (22)
p=0.23
p=0.25
p=0.40
p=0.40 p=0.98p=0.98
MNA-SF N
   Mean +/- SD
   ≥ 12§ n (%)
   < 11 n (%)
57
11.1 +/- 2
25 (44)
32 (56)
55
9.9 +/- 2
16 (29)
39 (71)
50
11.5 +/- 2
27 (54)
23 (46)
p<0.01
p<0.01
p=0.19
p=0.13
51
11.0 +/- 2
23 (45)
28 (55)
48
11.3 +/- 2
29 (60)
19 (40)
46
11.4 +/- 2
23 (50)
23 (50)
p=0.24
p=0.32
p=0.23
p=0.21
p<0.01
p<0.01
CCI N
   Mean +/- SD
   0§ n (%)
   1 n (%)
   >=2 n (%)
54
0.6 +/- 1
32 (59)
12 (22)
10 (19)
53
0.7 +/- 1
32 (60)
10 (19)
11 (21)
49
0.7 +/- 1
28 (57)
12 (25)
9 (18)
p=0.42
p=0.48
p=0.16
p=0.78
52
1.1 +/- 2
27 (52)
12 (23)
13 (25)
50
1.1 +/- 2
27 (54)
10 (20)
13 (26)
46
1.2 +/- 2
22 (48)
11 (24)
13 (28)
p=0.86
p=0.97
p=0.35
p=0.91
p=0.63θ
p=0.86 θ
G8 N
   Mean +/- SD
   >14 n (%)
   ≤ 14 n (%)
56
14.2 +/- 2
28 (50)
28 (50)
NA NA N/A N/A
52
13.7 +/- 2
22 (42)
30 (58)
NA NA N/A N/A N/A
Global QoL N
   Mean +/- SD
57
64.2 +/- 
17
56
58.5 +/- 
20
50
69.5 +/- 22
p=0.06
p=0.05
p=0.11
p=0.08
52
63.8 +/- 17
48
64.6 +/- 
20
46
63.6 +/- 23
p=0.83
p=0.83
p=0.73
p=0.96
p=0.02
p=0.03
Abbreviations. SD: Standard Deviation; CI: Confidence Interval; ADL: Activities of Daily Living; IADL: Instrumental 
Activities of Daily Living; MMSE: Mini Mental State Examination; GDS: Geriatric Depression Scale; MNA-SF: Mini 
Nutritional Assessment-Short Form; MNA: Mini Nutritional Assessment
§: Maximum score, no abnormalities
α: calculation based on probability of being fit or vulnerable by time and study arm 
β: calculation based on probability of falling by time and study arm 
θ: calculation based on probability of having the lowest score at CCI, by time and study arm 
p-values in italic font show results corrected for patient frailty level at baseline
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Figure 2: Evolution over time of geriatric assessment parameters in the Chemo and Control Groups. * Designates 
statistical significant (p≤ 0.05) differences at T1 or T2, compared to T0, within the Chemo group (green asterisk) or the Control group 
(blue asterisk) A. Predicted probability (+95% CI) of being ‘fit or vulnerable’ by Time and Study arm, by Balducci B. Mean Leuven 
Oncogeriatric Frailty Score (LOFS) (+95% CI) by Time and Study arm C. Mean score for Activities of Daily Living (ADL) (+95% CI) by 
Time and Study arm D. Mean score for instrumental Activities of Daily Living (iADL) (+95% CI) by Time and Study arm E. Mean score 
for Mini Mental State Evaluation (MMSE) (+95% CI) by Time and Study arm F. Mean score for Mini Nutritional Assessment Short Form 
(MNA-SF) (+ 95% CI) by Time and Study arm G. Mean score for Geriatric Depression Scale (GDS) (+95% CI) by Time and Study arm 
H. Mean Global Quality of Life (+95% CI) by Time and Study arm
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The absence of a pronounced aging/frailty-inducing 
effect of chemotherapy was further corroborated by 
measurements of some of the principal well-established 
aging biomarkers, such as LTL and IL-6. LTL was 
comparable in both groups at baseline and progressively 
decreased over the 1-year time course of the study with 
no significant difference between the two groups. This 
is in line with the well-known age-related process of 
progressive telomere attrition [6, 7, 44] but does not 
support the hypothesis that the aging process is accelerated 
by chemotherapy. Similar to LTL, the plasma marker 
IL-6 [13] did not reveal chemotherapy-induced aging 
progression when considering the evolution over the 
1-year study period. On the other hand, several of the 
additional plasma biomarkers that have previously been 
associated with aging [13, 15, 21, 22, 25, 27, 45-47], did 
suggest a slight aging-promoting effect of chemotherapy: 
decreases in IL-10 and IGF-1 and increases in TNFα and 
MCP-1 from baseline to 1 year were significantly more 
pronounced in the CTG compared to the CG, suggesting 
accelerated  biological aging. However, we tend to 
consider the clinical impact of alterations in only a few 
biomarkers that contribute to the so-called ‘inflammaging’ 
phenomenon rather minimal, especially as more robust 
aging biomarkers do not appear to show the same trend. 
Although geriatric assessment parameters and the 
patient’s perception of QoL did not change significantly 
at 1 year, one might argue that clinical changes may 
not immediately become visible, but might remain 
subclinical for a longer period of time. On the other hand, 
it was shown by Benitez-Beluga et al. [37] that biological 
changes induced by chemotherapy can recover to normal 
after a sufficiently long period of follow-up. Therefore, 
the transient changes observed shortly after treatment 
in our study, seem not very likely to have any clinical 
significance on the long term.
Of all evaluated biomarkers, IL-6 showed the 
strongest correlation with chronological age and LOFS, 
confirming its robustness as an aging biomarker as 
previously described [13]. Associations of the other aging 
biomarkers were less prominent and mostly not significant. 
It should be noted, though, that the cohort examined in this 
study only comprised elderly people within narrow age 
range (70 – 90 years). Hence, the lack of association with 
chronological age in this study does not necessarily imply 
that these markers are not age-related at all. 
From the clinical perspective, aging biomarkers 
that would be predictive for chemotherapy-associated 
adverse events (toxicity, unplanned readmissions), would 
be highly relevant. However, we found that none of the 
biomarkers tested was associated with grade II-III-IV 
toxicity or unplanned readmissions, and neither were the 
Table 5: Cumulative toxicity
Cumulative adverse event Chemotherapy Group /Control groupGrade in %
1 2 3 4
Febrile neutropenia T0 → T1 0 / 0 0 / 0 13 / 0 0 / 0
T1 → T2 0 / 0 0 / 0 0 / 0 0 / 0
Anemia T0 → T1 63 / 18 11 / 8 2 / 0 0 / 0
T1 → T2 18 / 25 2 / 4 0 / 0 0 / 0
Diarrhea T0 → T1 26 / 2 4 / 0 2 / 0 0 / 0
T1 → T2 2 / 0 2 / 0 0 / 0 0 / 0
Nausea/vomiting T0 → T1 41 / 2 7 / 0 0 / 0 0 / 0
T1 → T2 0 / 4 0 / 0 0 / 0 0 / 0
Anorexia T0 → T1 46 / 6 9 / 0 2 / 0 0 / 0
T1 → T2 6 / 2 6 / 4 0 / 0 0 / 0
Fatigue T0 → T1 44 / 26 22 / 0 2 / 2 0 / 0
T1 → T2 30 / 19 2 / 4 2 / 0 0 / 0
Pain T0 → T1 30 / 28 9 / 2 0 / 0 0 / 0
T1 → T2 40 / 53 4 / 2 0 / 0 0 / 0
Mucositis T0 → T1 24 / 0 2 / 0 2 / 0 0 / 0
T1 → T2 1 / 0 0 / 0 0 / 0 0 / 0
Sensory neuropathy T0 → T1 15 / 4 0 / 0 0 / 0 0 / 0
T1 → T2 8 / 0 0 / 0 0 / 2 0 / 0
Rash T0 → T1 17 / 0 0 / 0 0 / 0 0 / 0
T1 → T2 2 / 0 0 / 0 0 / 0 0 / 0
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clinical frailty scores (Balducci/LOFS) 
Due to the non-randomized design of the study, we 
cannot exclude some selection bias. The CG was in fact 
slightly less fit than the CTG at the start of the study, as 
apparent from LOFS and biomarkers at baseline and by 
long-term frequency of hospitalization events (between T1 
and T2). This was not unexpected, since not only patients 
at low risk for cancer recurrence, but also patients too frail 
for chemotherapy, were included as controls. However, 
this does not influence our conclusions, as we do not 
compare absolute values of test results at a specific time 
point, but rather consider differences in evolution over 
time of clinical and biological aging markers between the 
groups. 
Taken together, we conclude that chemotherapy, 
after 1 year, does not significantly influence clinical aging 
parameters, nor does it induce an altered evolution in the 
most robust aging biomarkers recognized to date (i.e. LTL 
and IL-6). Nevertheless, other aging biomarkers (MCP-1, 
TNF-α, IL-10 and IGF-1) evaluated in this study indicated 
a (mild) potential aging promoting effect of chemotherapy. 
We found, however, no evidence that changes in these 
circulating molecules, as a consequence of chemotherapy, 
do result in clinically relevant changes in frailty, in 
morbidity, or in higher (all-cause) mortality.
Our study is the first to report a prospective 
comparison of exclusively older breast cancer patients 
receiving or not receiving post-operative chemotherapy 
by measuring several different clinical (GA) and 
biological aging markers. The results demonstrate that 
although some biological markers do change during and 
after chemotherapy, there is no convincing evidence of 
a clinically relevant acceleration of the aging process. 
This is an important finding because it emphasizes that 
chemotherapy should not be denied to older breast cancer 
patients solely because of their advanced age.
PATIENTS AND METHODS
Patient population and clinical assessment
This prospective, multicentre, non-interventional 
study accrued patients in 2 academic and 3 regional 
hospitals in Belgium from 2009 until 2012 (www.
clinicaltrials.gov/ NCT00849758). Eligible patients for 
the chemotherapy group (CTG) were female, ≥70 years 
old with early invasive breast cancer for whom adjuvant 
chemotherapy was planned according to established risk 
factors and international guidelines [48]. The scheduled 
therapy consisted of docetaxel at a dose of 75 mg/m2 and 
cyclophosphamide at 600 mg/m2 every 3 weeks for a total 
of 4 cycles (TC scheme)[41-43]. Primary prophylaxis 
with G-CSF (granulocyte-colony stimulating factor) 
was administered as per standard practice guidelines. 
In parallel, we enrolled a control group (CG) consisting 
of early breast cancer patients ≥70 years old for whom 
chemotherapy was not indicated (or indicated, but 
judged not to be feasible), and who were administered 
an aromatase inhibitor as sole adjuvant systemic therapy. 
Patients either or not received adjuvant radiotherapy 
according to institution policy. In the chemotherapy group, 
patients with hormone sensitive tumors also received an 
endocrine therapy after completion of chemotherapy. 
Trastuzumab was associated to the adjuvant chemotherapy 
if the tumor was HER2 positive. 
The study was approved by the Ethical Committee 
of the participating hospitals and written informed consent 
was obtained from all patients.
Patients were enrolled after surgery. They underwent 
blood sampling, geriatric assessment (GA) and Quality of 
Life (QoL) evaluation at three time points. The first time 
point was between 3 and 6 weeks after surgery, and always 
before the first chemotherapy administration. The second 
time point was approximately 3 months after inclusion 
(day of last chemotherapy), and the last time point was 
around 1 year after inclusion.
We performed a G8 [49]_ENREF_44 screening 
test[49] at baseline, and a GA, at each time point. 
Social data (age, living situation, marital status and 
educational level) were assessed. Functional status was 
measured by Katz’s Activities of Daily Living (ADL) 
and by Lawton’s instrumental Activities of Daily Living 
(iADL) scales. A fall history (number of falls during the 
previous 12 months and presence of fall-related injury) 
was recorded. We determined cognitive status with the 
Mini Mental State Examination (MMSE) and mood with 
the 15-item Geriatric Depression Scale (GDS-15). The 
nutritional status was assessed using the Mini Nutritional 
Assessment-Short Form (MNA-SF). Polypathology 
and severity of medical problems were measured with 
the Charlson Comorbidity Index (CCI). Geriatric scales 
have been described in detail by Kenis C. et al [50]. 
GA results were categorized into “fit”, “vulnerable” and 
“frail” groups according to Balducci [51, 52]. However, 
as this categorisation has limitations (e.g. age above 
85 is always considered “frail”), we developed a new 
scoring system, the Leuven Oncogeriatric Frailty Score 
(LOFS), to summarize GA results in a more refined linear 
score ranging from 10 (very fit) to 0 (very frail). Details 
are described in appendix 1, and in one of our previous 
publications [4]. 
Classical oncological parameters such as Eastern 
Cooperative Oncology Group - Performance Status 
(ECOG-PS), tumor characteristics (i.e. tumor subtype 
according St-Gallen criteria [53] and TNM) and treatment 
details were recorded. Adverse Events according 
to CTCAE v4.0 and unplanned readmissions were 
recorded. An unplanned readmission was identified as 
a subsequent or repeat hospitalization, which could not 
have been foreseen at the time of baseline time point [54]. 
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Polypharmacy was assessed by the number of different 
registered drugs (www.bcfi.be) the patient had been taking 
during the week preceding inclusion. QoL was assessed 
with the EORTC QLQ-C30 questionnaire, from which the 
last two questions (question 29 and 30) were further used 
to determine ‘global QoL’. 
Blood sampling and measurement of aging 
biomarkers
At each time point, blood was sampled in 4-mL 
EDTA K2E tubes for plasma isolation and leukocyte DNA 
extraction. 
Mean leukocyte telomere length (LTL) was 
measured on leukocyte DNA by qPCR [44] and plasma 
levels of IL-6, IL-10, IGF-1, TNF-α, MCP-1, and 
RANTES were assessed by ELISA. Detailed procedures 
are described in appendix 2.
Statistics and Endpoints
Statistics and endpoints are described in appendix 3.
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